Prospective validation of a model-informed precision dosing tool for vancomycin treatment in neonates.
Antimicrob Agents Chemother
; 68(5): e0159123, 2024 May 02.
Article
en En
| MEDLINE
| ID: mdl-38578080
ABSTRACT
We recruited 48 neonates (50 vancomycin treatment episodes) in a prospective study to validate a model-informed precision dosing (MIPD) software. The initial vancomycin dose was based on a population pharmacokinetic model and adjusted every 36-48 h. Compared with a historical control group of 53 neonates (65 episodes), the achievement of a target trough concentration of 10-15 mg/L improved from 37% in the study to 62% in the MIPD group (P = 0.01), with no difference in side effects.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Vancomicina
/
Antibacterianos
Límite:
Female
/
Humans
/
Male
/
Newborn
Idioma:
En
Revista:
Antimicrob Agents Chemother
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estonia